COVID-19: A Phase 3, Randomized, Observer-blinded, Multicenter Clinical Study Evaluating the Immunogenicity, Safety, and Reactogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV, When Co-administered With a Licensed Quadrivalent Influenza Vaccine Versus Separate Administration of the Two Vaccines in Adults 60 Years of Age and Older
Latest Information Update: 21 Nov 2022
At a glance
- Drugs Influenza vaccine quadrivalent Abbott Biologicals (Primary) ; Zorecimeran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Acronyms CV-NCOV-011
- Sponsors Bayer
- 16 Aug 2021 According to a CureVac media release, this study is currently being redesigned based on inconclusive efficacy of CVnCoV in adults above the age of 60 in the HERALD study.
- 04 Aug 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jun 2021 Planned End Date changed from 30 Aug 2022 to 15 Nov 2022.